Amelia Harper,
Amelia Harper is a journalist who reports for Sky News from various locations around the world.
63%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
85%
Examples:
- The article does not provide any evidence or sources for some of its claims, such as Dr Clare Hambling's statement about Type 1 diabetes being easily missed.
- The article seems to have a positive bias towards the NHS and its healthcare initiatives.
Conflicts of Interest
50%
Examples:
- However, there is a potential conflict of interest with the source of the article. Sky News is owned by Rupert Murdoch's News UK, which may have an agenda or bias in reporting on healthcare issues.
- The author does not appear to have any clear conflicts of interest.
Contradictions
100%
Examples:
- However, there is a contradiction between the title and the content of the article. The title suggests that thousands of people with Type 1 diabetes will receive an artificial pancreas, but the article only mentions that it will be rolled out across England over five years.
- There are no major contradictions found in the article.
Deceptions
50%
Examples:
- For example, the author uses vague terms like 'ground-breaking' and 'thousands' without providing specific numbers or evidence. Additionally, the author does not disclose their name or affiliation in the biography.
- The article contains some deceptive practices.
Recent Articles
Revolutionizing Type 1 Diabetes: The NHS Rolls Out Artificial Pancreas System
Broke On: Thursday, 04 April 2024The NHS in England is set to roll out an artificial pancreas system, also known as a closed loop system, to people with Type 1 diabetes. The hybrid closed loop system will continually monitor a person's blood glucose levels and automatically adjust the amount of insulin given through a pump. This technology holds the power to redefine the lives of those with Type 1 diabetes by promising better quality of life as well as clinical outcomes.